Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

The signalling mechanisms of a novel mitochondrial complex I inhibitor prevent lipid accumulation and attenuate TNF-α-induced insulin resistance in vitro.

Leonard S, Tobin LM, Findlay JB.

Eur J Pharmacol. 2017 Apr 5;800:1-8. doi: 10.1016/j.ejphar.2017.01.007. Epub 2017 Jan 12.

PMID:
28088384
2.

Regulating the effects of GPR21, a novel target for type 2 diabetes.

Leonard S, Kinsella GK, Benetti E, Findlay JBC.

Sci Rep. 2016 May 31;6:27002. doi: 10.1038/srep27002.

3.

Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice.

Martin DS, Leonard S, Devine R, Redondo C, Kinsella GK, Breen CJ, McEneaney V, Rooney MF, Munsey TS, Porter RK, Sivaprasadarao A, Stephens JC, Findlay JB.

J Mol Endocrinol. 2016 Apr;56(3):261-71. doi: 10.1530/JME-15-0225. Epub 2016 Jan 12.

PMID:
26759391
4.

Analysis of the effect of a novel therapeutic for type 2 diabetes on the proteome of a muscle cell line.

Young PA, Leonard S, Martin DS, Findlay JB.

Proteomics. 2016 Jan;16(1):70-9. doi: 10.1002/pmic.201500050. Epub 2015 Dec 12.

PMID:
26573124
5.

The effect of retinol binding protein on the proteome of C2C12 muscle cells.

Young PA, Leonard S, Martin DS, Findlay JB.

Diabetes Metab Res Rev. 2016 May;32(4):379-90. doi: 10.1002/dmrr.2764. Epub 2015 Dec 3.

PMID:
26556762
6.

Production of functional human vitamin A transporter/RBP receptor (STRA6) for structure determination.

Breen CJ, Martin DS, Ma H, McQuaid K, O'Kennedy R, Findlay JB.

PLoS One. 2015 Mar 27;10(3):e0122293. doi: 10.1371/journal.pone.0122293. eCollection 2015.

7.

High prevalence of PRPH2 in autosomal dominant retinitis pigmentosa in france and characterization of biochemical and clinical features.

Manes G, Guillaumie T, Vos WL, Devos A, Audo I, Zeitz C, Marquette V, Zanlonghi X, Defoort-Dhellemmes S, Puech B, Said SM, Sahel JA, Odent S, Dollfus H, Kaplan J, Dufier JL, Le Meur G, Weber M, Faivre L, Cohen FB, Béroud C, Picot MC, Verdier C, Sénéchal A, Baudoin C, Bocquet B, Findlay JB, Meunier I, Dhaenens CM, Hamel CP.

Am J Ophthalmol. 2015 Feb;159(2):302-14. doi: 10.1016/j.ajo.2014.10.033. Epub 2014 Nov 5.

8.

Expression, characterization and ligand specificity of lipocalin-1 interacting membrane receptor (LIMR).

Hesselink RW, Findlay JB.

Mol Membr Biol. 2013 Aug-Sep;30(5-6):327-37. doi: 10.3109/09687688.2013.823018.

PMID:
23964685
9.

The melanocortin 4 receptor: oligomer formation, interaction sites and functional significance.

Chapman KL, Findlay JB.

Biochim Biophys Acta. 2013 Feb;1828(2):535-42. doi: 10.1016/j.bbamem.2012.10.011. Epub 2012 Oct 23.

10.

Pharmacological chaperones increase the cell-surface expression of intracellularly retained mutants of the melanocortin 4 receptor with unique rescuing efficacy profiles.

Ward NA, Hirst S, Williams J, Findlay JB.

Biochem Soc Trans. 2012 Aug;40(4):717-20. doi: 10.1042/BST20110764. Review.

PMID:
22817722
11.

Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.

Campos-Sandoval JA, Redondo C, Kinsella GK, Pal A, Jones G, Eyre GS, Hirst SC, Findlay JB.

J Med Chem. 2011 Jul 14;54(13):4378-87. doi: 10.1021/jm200256g. Epub 2011 Jun 7.

PMID:
21591606
12.

An analysis of the phosphoproteome of immune cell lines exposed to the immunomodulatory mycotoxin deoxynivalenol.

Nogueira da Costa A, Keen JN, Wild CP, Findlay JB.

Biochim Biophys Acta. 2011 Jul;1814(7):850-7. doi: 10.1016/j.bbapap.2011.04.001. Epub 2011 Apr 13.

PMID:
21513824
13.

Proteomic analysis of the effects of the immunomodulatory mycotoxin deoxynivalenol.

Nogueira da Costa A, Mijal RS, Keen JN, Findlay JB, Wild CP.

Proteomics. 2011 May;11(10):1903-14. doi: 10.1002/pmic.201000580. Epub 2011 Apr 4.

PMID:
21462343
14.

Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.

Chapman KL, Kinsella GK, Cox A, Donnelly D, Findlay JB.

J Mol Biol. 2010 Aug 20;401(3):433-50. doi: 10.1016/j.jmb.2010.06.028. Epub 2010 Jun 19.

15.

A site-directed cross-linking approach to the characterization of subunit E-subunit G contacts in the vacuolar H+-ATPase stator.

Jones RP, Durose LJ, Phillips C, Keen JN, Findlay JB, Harrison MA.

Mol Membr Biol. 2010 Aug;27(4-6):147-59. doi: 10.3109/09687681003796441.

PMID:
20446876
16.

Expression and characterization of recombinant human retinol-binding protein in Pichia pastoris.

Wysocka-Kapcinska M, Campos-Sandoval JA, Pal A, Findlay JB.

Protein Expr Purif. 2010 May;71(1):28-32. doi: 10.1016/j.pep.2010.01.015. Epub 2010 Jan 20.

PMID:
20093188
17.

Expression and structural characterization of peripherin/RDS, a membrane protein implicated in photoreceptor outer segment morphology.

Vos WL, Vaughan S, Lall PY, McCaffrey JG, Wysocka-Kapcinska M, Findlay JB.

Eur Biophys J. 2010 Mar;39(4):679-88. doi: 10.1007/s00249-009-0553-7. Epub 2009 Nov 18.

PMID:
19921174
18.

Proteomic analysis of IgE-mediated secretion by LAD2 mast cells.

Gage MC, Keen JN, Buxton AT, Bedi MK, Findlay JB.

J Proteome Res. 2009 Aug;8(8):4116-25. doi: 10.1021/pr900108w.

PMID:
19480418
19.

Electrophoretic field gradient focusing with on-column detection by fluorescence quenching.

Ansell RJ, Tuñón PG, Wang Y, Myers P, Ivory CF, Keen JN, Findlay JB.

Analyst. 2009 Feb;134(2):226-9. doi: 10.1039/b815446e. Epub 2008 Dec 24.

PMID:
19173041
20.

Deciphering soluble and membrane protein function using yeast systems (Review).

Bao L, Redondo C, Findlay JB, Walker JH, Ponnambalam S.

Mol Membr Biol. 2009 Apr;26(3):127-35. doi: 10.1080/09687680802637652. Epub 2008 Dec 26. Review.

PMID:
19115141
21.

Investigation of the structure and function of a Shewanella oneidensis arsenical-resistance family transporter.

Xia X, Postis VL, Rahman M, Wright GS, Roach PC, Deacon SE, Ingram JC, Henderson PJ, Findlay JB, Phillips SE, McPherson MJ, Baldwin SA.

Mol Membr Biol. 2008 Dec;25(8):691-705. doi: 10.1080/09687680802535930.

PMID:
19039703
22.

The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease.

Howes JM, Keen JN, Findlay JB, Carter AM.

Diab Vasc Dis Res. 2008 Sep;5(3):205-12. doi: 10.3132/dvdr.2008.033. Review.

PMID:
18777494
23.

Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma.

Breton J, Gage MC, Hay AW, Keen JN, Wild CP, Donnellan C, Findlay JB, Hardie LJ.

J Proteome Res. 2008 May;7(5):1953-62. doi: 10.1021/pr7007835. Epub 2008 Apr 9.

PMID:
18396902
24.

Incorporation of transmembrane peptides from the vacuolar H(+)-ATPase in phospholipid membranes: spin-label electron paramagnetic resonance and polarized infrared spectroscopy.

Kóta Z, Páli T, Dixon N, Kee TP, Harrison MA, Findlay JB, Finbow ME, Marsh D.

Biochemistry. 2008 Mar 25;47(12):3937-49. doi: 10.1021/bi7025112. Epub 2008 Feb 29.

PMID:
18307317
25.

Identification of the retinol-binding protein (RBP) interaction site and functional state of RBPs for the membrane receptor.

Redondo C, Vouropoulou M, Evans J, Findlay JB.

FASEB J. 2008 Apr;22(4):1043-54. Epub 2007 Nov 8.

PMID:
17991731
26.

Interaction of spin-labeled inhibitors of the vacuolar H+-ATPase with the transmembrane Vo-sector.

Dixon N, Páli T, Kee TP, Ball S, Harrison MA, Findlay JB, Nyman J, Väänänen K, Finbow ME, Marsh D.

Biophys J. 2008 Jan 15;94(2):506-14. Epub 2007 Sep 14.

27.

Structure and localization of an essential transmembrane segment of the proton translocation channel of yeast H+-V-ATPase.

Duarte AM, Wolfs CJ, van Nuland NA, Harrison MA, Findlay JB, van Mierlo CP, Hemminga MA.

Biochim Biophys Acta. 2007 Feb;1768(2):218-27. Epub 2006 Aug 2.

28.

An expanded and flexible form of the vacuolar ATPase membrane sector.

Clare DK, Orlova EV, Finbow MA, Harrison MA, Findlay JB, Saibil HR.

Structure. 2006 Jul;14(7):1149-56.

29.

The retinol-binding protein system: a potential paradigm for steroid-binding globulins?

Redondo C, Burke BJ, Findlay JB.

Horm Metab Res. 2006 Apr;38(4):269-78. Review.

PMID:
16700009
30.

The application of proteomics to diabetes.

Scott EM, Carter AM, Findlay JB.

Diab Vasc Dis Res. 2005 May;2(2):54-60. Review.

PMID:
16305059
31.

Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H+-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain.

Whyteside G, Meek PJ, Ball SK, Dixon N, Finbow ME, Kee TP, Findlay JB, Harrison MA.

Biochemistry. 2005 Nov 15;44(45):15024-31.

PMID:
16274249
32.

The first de novo-designed antagonists of the human NK(2) receptor.

Ali MA, Bhogal N, Findlay JB, Fishwick CW.

J Med Chem. 2005 Sep 8;48(18):5655-8.

PMID:
16134933
33.

Defined sites of interaction between subunits E (Vma4p), C (Vma5p), and G (Vma10p) within the stator structure of the vacuolar H+-ATPase.

Jones RP, Durose LJ, Findlay JB, Harrison MA.

Biochemistry. 2005 Mar 15;44(10):3933-41. Erratum in: Biochemistry. 2005 Sep 6;44(35):11924.

PMID:
15751969
34.

Methionine-rich repeat proteins: a family of membrane-associated proteins which contain unusual repeat regions.

Weiss JL, Evans NA, Ahmed T, Wrigley JD, Khan S, Wright C, Keen JN, Holzenburg A, Findlay JB.

Biochim Biophys Acta. 2005 Mar 1;1668(2):164-74. Epub 2005 Jan 26.

35.

MTSEA prevents ligand binding to the human melanocortin-4 receptor by modification of cysteine 130 in transmembrane helix 3.

Cox A, Donnelly D, Kaur M, Cheetham SC, Cockcroft VB, Findlay JB.

FEBS Lett. 2005 Jan 3;579(1):285-91.

36.

Automatic generation and evaluation of sparse protein signatures for families of protein structural domains.

Blades MJ, Ison JC, Ranasinghe R, Findlay JB.

Protein Sci. 2005 Jan;14(1):13-23.

37.

Evidence to support a spectrum of active states for the glucagon receptor.

Strudwick N, Bhogal N, Evans NA, Blaney FE, Findlay JB.

Biochem Soc Trans. 2004 Dec;32(Pt 6):1037-9.

PMID:
15506957
38.

Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector.

Páli T, Whyteside G, Dixon N, Kee TP, Ball S, Harrison MA, Findlay JB, Finbow ME, Marsh D.

Biochemistry. 2004 Sep 28;43(38):12297-305.

PMID:
15379568
39.
40.

Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.

López de Maturana R, Treece-Birch J, Abidi F, Findlay JB, Donnelly D.

Protein Pept Lett. 2004 Feb;11(1):15-22.

PMID:
14965274
41.

Thermodynamics of binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the major urinary protein.

Bingham RJ, Findlay JB, Hsieh SY, Kalverda AP, Kjellberg A, Perazzolo C, Phillips SE, Seshadri K, Trinh CH, Turnbull WB, Bodenhausen G, Homans SW.

J Am Chem Soc. 2004 Feb 18;126(6):1675-81.

PMID:
14871097
42.

New biophysical probes for structure-activity analyses of vacuolar-H+ -ATPase enzymes.

Dixon N, Pali T, Ball S, Harrison MA, Marsh D, Findlay JB, Kee TP.

Org Biomol Chem. 2003 Dec 21;1(24):4361-3. Epub 2003 Nov 3.

PMID:
14685305
43.

Expression, purification and spectroscopic studies of full-length Kir3.1 channel C-terminus.

Leach RN, Boyett MR, Findlay JB.

Biochim Biophys Acta. 2003 Dec 1;1652(2):83-90.

PMID:
14644043
44.

Structure and function of the vacuolar H+-ATPase: moving from low-resolution models to high-resolution structures.

Harrison M, Durose L, Song CF, Barratt E, Trinick J, Jones R, Findlay JB.

J Bioenerg Biomembr. 2003 Aug;35(4):337-45. Review.

PMID:
14635779
45.

Quaternary structure of alpha-crustacyanin from lobster as seen by small-angle X-ray scattering.

Dellisanti CD, Spinelli S, Cambillau C, Findlay JB, Zagalsky PF, Finet S, Receveur-Bréchot V.

FEBS Lett. 2003 Jun 5;544(1-3):189-93.

46.
47.

Effects of ACh and adenosine mediated by Kir3.1 and Kir3.4 on ferret ventricular cells.

Dobrzynski H, Janvier NC, Leach R, Findlay JB, Boyett MR.

Am J Physiol Heart Circ Physiol. 2002 Aug;283(2):H615-30.

48.

A protein chemical approach to channel structure and function: the proton channel of the vacuolar H(+)-ATPase.

Findlay JB, Harrison MA.

Novartis Found Symp. 2002;245:207-18; discussion 218-22, 261-4. Review.

PMID:
12027009
50.

Supplemental Content

Loading ...
Support Center